Company Logo

5.69 USD

-0.31 (-5.17%)

Last updated Oct 30, 1:30 PM

Yesterday High

$6.18

Yesterday Low

$5.90

52w High

$18.70

52w Low

$4.40

Market Cap.

$481.5M

52w Change

-51.58%

This is a preview of the full version of Prosperse

Trending News

VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity t...

Verve Therapeutics, Inc. is facing a class action lawsuit alleging the company made false and/or misleading statements about the circumstances under which its Heart-1 Phase 1b clinical trial of VERVE-101 would be halted, as well as overstating the potential benefits of its proprietary lipid nanopart...

Bronstein, Gewirtz & Grossman, Llc

Sep 15, 2024

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Acti...

Rosen Law Firm is encouraging investors of Verve Therapeutics, Inc. to seek legal counsel before the October 28, 2024 deadline in a securities class action lawsuit filed by the firm. The lawsuit alleges that Verve Therapeutics made false and/or misleading statements about the circumstances surroundi...

N/A

Sep 13, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm

The Schall Law Firm has filed a securities fraud lawsuit against Verve Therapeutics, Inc. (VERV) for making false and misleading statements about its Heart-1 Phase 1b clinical trial and the benefits of its proprietary lipid nanoparticle (LNP) delivery system.

Prnewswire

Sep 13, 2024

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors ...

Bragar Eagel & Squire, P.C. has filed class action lawsuits against WEBTOON, Verve Therapeutics, and Ardelyx, alleging that the companies made false and/or misleading statements about their business, operations, and prospects.

N/A

Sep 10, 2024

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action...

Rosen Law Firm is encouraging investors of Verve Therapeutics, Inc. to secure counsel before the October 28, 2024 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Verve Therapeutics made false and/or misleading statements about the circumstances under which a cl...

N/A

Sep 9, 2024

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Acti...

Rosen Law Firm is encouraging investors of Verve Therapeutics, Inc. to seek legal counsel before the October 28, 2024 deadline in a securities class action lawsuit. The lawsuit alleges that Verve Therapeutics made false and misleading statements about its VERVE-101 clinical trial and the potential b...

N/A

Sep 5, 2024

Login to view more news

Dive into the world of investing with Prosperse

Explore our recent articles to learn more about how Prosperse can help you achieve your financial goals.

Read more news from Prosperse